UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported) January 22, 2001

COMMONWEALTH BIOTECHNOLOGIES, INC.
(Exact Name of Registrant as Specified in Charter)

Virginia	001-13467	56-1641133
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

601 Biotech Drive, Richmond, Virginia 23235
(Address of Principal Executive Offices) (Zip Code)

Registrant's telephone number, including area code: (804) 648-3820

N/A
(Former Name or Former Address, if Changed Since Last Report)

Item 5. Other Events.

On January 22, 2001, the Registrant announced the resignation of one director and the election of three additional members to the Registrant's Board of Directors. A copy of the press release relating to the announcement is attached as an exhibit hereto.

Item 7. Financial Statements and Exhibits.

(a) Financial Statements of Businesses Acquired.

Not applicable.

(b) Pro Forma Financial Information.

Not applicable.

(c) Exhibits.

99.1 Press Release, dated January 22, 2001, relating to the resignation of one director and the election of three additional members to the Registrant's Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

COMMONWEALTH BIOTECHNOLOGIES, INC.

By: /s/ Richard J. Freer, Ph.D.

Richard J. Freer, Ph.D.
Chairman

January 22, 2001

EXHIBIT INDEX

Number	Description of Exhibit
99.1	Press Release, dated January 22, 2001, relating to the resignation of one director and the election of three additional members to the Registrant's Board of Directors.

Exhibit 99.1

FOR IMMEDIATE RELEASE

Contact: Bill Ballas
(804) 754-2714
ballas1@erols.com

COMMONWEALTH BIOTECHNOLOGIES, INC. ANNOUNCES ELECTION OF NEW DIRECTORS.

RICHMOND, VA (January 22, 2001) - Commonwealth Biotechnologies, Inc. (NASDAQ small cap exchange: CBTE) today announced the election of three new members to its Board of Directors. The company also announced that former-governor, now Senator George Allen of Virginia has resigned his seat on the Board.

The newly elected members of the Board are Mr. Everette G. ("Buddy") Allen, Jr., Chairman and senior partner in the law firm of Hirschler, Fleischer, Weinberg, Cox and Allen, PC, in Richmond,VA; Dr. Donald McAfee, Chairman and Chief Technical Officer of Discovery Therapeutics, Inc., Richmond, VA; and Mr. Samuel P. Sears, Jr., a nationally recognized attorney who specializes in management and negotiation of mergers and acquisitions.

"We are very pleased to have been able to attract such high quality new members to the Board. They will each bring a unique perspective which, I believe, complements the continuing employee and non-employee members of the Board," said Richard J. Freer, Ph.D., Chairman of CBI.

They will join the continuing Non-employee Board Members, Dr. Raymond Cypess, President and CEO of ATCC, Inc., Manassas, VA, and Mr. L. McCarthy Downs, III, Chairman, Anderson and Strudwick, Inc, Richmond, VA, and the three Employee Board Members, Dr. Richard J. Freer, Chairman, Dr. Robert B. Harris, President, and Mr. Thomas R. Reynolds, Senior Vice President.

Commenting on the resignation of Senator Allen, Freer said, "Due to his new responsibilities, Senator Allen would have a conflict of interest were he to continue to serve on the Board. His insights and positive support will be sorely missed. We, of course, wish him much success in Washington and look forward to his pro-business agenda reaping benefits for CBI, the Commonwealth, and the Nation."

Founded in 1992, CBI is located in Gateway Centre, 601 Biotech Drive, Richmond, Virginia 23235 (1-800-735-9224). CBI occupied this 32,000 square foot facility in December 1998 and currently employs a staff of 40 including twelve doctoral scientists. CBI provides comprehensive research and development services to more than 1,500 private, government, and academic customers in the global biotechnology industry. For more information, visit CBI on the web at www.cbi-biotech.com.

Any statements contained in this release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties as identified in the Company's filings with the Securities and Exchange Commission. Actual results, events or performance may differ materially.

Readers are cautioned not to place undo reliance on these forward-looking statements, which speak only as the date hereof. The company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.